Many supporters believe Robert Califf checks all the boxes, but if nominated he would also face many familiar confirmation challenges.
Stakeholders seem excited that Robert Califf could be tapped again to head the US Food and Drug Administration, but reaching the commissioner’s office a second time may be tougher, with many of the same issues raised during his first confirmation still lingering.
Califf is a top target for the nomination, the Washington Post first reported. The selection process is not complete;...
Recent studies show that spaceflight can significantly weaken astronauts’ immune systems, making them more susceptible to infections and health complications during and after missions. Understanding these changes is crucial for ensuring the safety of future long-duration space travelers.
Recent ODAC meetings suggest the FDA will expand focus beyond applications with pending approval decisions to refining trial designs and drug labels for competitors.
The US FDA Commissioner pushed for a rebalancing of the US’s pharmaceutical supply chains while also stressing that there is a role for US-China commerce that would be risky to compromise.
Recent ODAC meetings suggest the FDA will expand focus beyond applications with pending approval decisions to refining trial designs and drug labels for competitors.
The US FDA Commissioner pushed for a rebalancing of the US’s pharmaceutical supply chains while also stressing that there is a role for US-China commerce that would be risky to compromise.
